Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 34th Annual J.P. Morgan Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:30 p.m. PT (7:30 p.m. ET) on Wednesday, January 13, 2016 in San Francisco.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
CONTACTS: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
